Abstract 2494
Background
CAR-T cells are a new cancer treatment, where T cells are taken from the patient and modified in a laboratory to target cancer cells. There have been some promising results from early clinical trials, which have led to two products being made available to patients in the NHS. Axicabtagene ciloleucel for relapsed/refractory B-cell lymphoma patients and tisagenlecleucel for relapsed/refractory B-cell lymphoma patients and relapsed/refractory B-ALL patients under the age of 25. There are multiple clinical trials in progress throughout Europe, mostly in the haematology setting, with some in oncology. There are significant toxicities to this treatment modality and this is a complex heavily pre-treated patient population. Education of the wider nursing and multi professional team is therefore crucial. A new Lecturer Practitioner role was established, to focus on CAR-T. This poster explores nurses’ learning needs associated with introducing CAR-T therapy in a specialist cancer hospital in London, UK.
Methods
Data has been collected through evaluation of previous nursing educational initiatives in CAR-T therapy, which aimed to identify further learning needs. Further data collection is in development.
Results
Although this work is on-going, initial findings indicate that nurses require more education and support particularly around managing toxicities and patient expectations. Challenges for educating nurses also include uncertainties around the long-term effects of this treatment modality.
Conclusions
CAR-T therapy is being implemented at multiple centres throughout the UK/Europe and it is evident that there are a multitude of future opportunities for career development for nurses in this area. The role of a Lecturer Practitioner in CAR-T at a specialist cancer hospital has been created to address some of the educational needs of the nursing and multi-professional team. The post holder is involved in a wide range of educational initiatives, from national bespoke study days and academic cancer care modules to ward based teaching. It is clear that there is a need for a role that combines clinical practice and academia, bridging the theory to practice gap and providing expert clinical knowledge to nurses caring for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Ellard: Honoraria (self): MolMed; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Kite Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract